COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab.
Mult Scler Relat Disord
; 52: 102983, 2021 Jul.
Article
in English
| MEDLINE | ID: covidwho-1213442
ABSTRACT
Since the recent approval of vaccines against COVID-19, efficacy concerns emerged for MS patients treated with immunosuppressive drugs. We report our experience in four patients, under cladribine (two) or under ocrelizumab (two) treatment, all with low lymphocyte count, three of them vaccinated after 3 months from the last dose with good immune response, one (under ocrelizumab) after 2 months, without developing an appropriate title of antibodies. This experience suggests that the discriminant for the response to the vaccine is not the lymphocyte count but the timing of the vaccination.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19
/
Multiple Sclerosis
Topics:
Vaccines
Limits:
Humans
Language:
English
Journal:
Mult Scler Relat Disord
Year:
2021
Document Type:
Article
Affiliation country:
J.msard.2021.102983
Similar
MEDLINE
...
LILACS
LIS